Magic Shave Powder Gold

Phase 1Small molecule

WWayne State University

Magic Shave Powder Gold is one of 12 small molecule programs targeting Folliculitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FolliculitisActive, not recruiting

FolliculitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Folliculitis

#DrugCompanyPhaseTrials

Lotrimin

Bayer

Approved

—2

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Approved

1 3

Garamycin

Qvar

Alphagan

1 6

Stelara

Johnson & Johnson

Phase 2

1 7

Olumiant

Eli Lilly

Phase 2

1 8

Humira

CCelltrion

Phase 2

1 9

Supramolecular Active Zinc

SSecond Affiliated Hospital of Xi'an Jiaotong University

Approved

1 10

Diprosone

LEO Pharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Folliculitis1 trial

Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae

Withdrawn·WWayne State University·Phase 1·NCT04220502

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Magic Shave Powder Gold. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Magic Shave Powder Gold compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Magic Shave Powder Gold. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wayne State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWayne State University

Magic Shave Powder Gold

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Folliculitis1 trial

References

Drug Info

Quick Facts

Related News